Investment Summary |
|
|---|---|
| Date | 2006-12-15 |
| Target | Affymax |
| Sector | Life Science |
| Sellers(s) |
Apax
Nexus Life Science Partners |
| Deal Type | IPO |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Private Equity Firm |
|---|---|
| Founded | 1981 |
| PE ASSETS | 60.0B USD |
| Size | Mega |
| Type | Sector Agnostic |
Apax Partners is a mega-sized private equity investment group, operating across the United States, Europe, Israel and Asia. Broad industry sectors of interest include tech & telecom, media, retail & consumer, healthcare, financial services, and business services. Apax will consider both minority and majority investment positions and prefers companies with strong market positions and growth potential. The Firm generally pursues platform acquisitions valued from €1 to €5 billion. Apax Partners was formed in 1981 and is based in London.
| DEAL STATS | # |
|---|---|
| Overall | 16 of 162 |
| Sector (Life Science) | 2 of 6 |
| Type (IPO) | 5 of 25 |
| State (California) | 1 of 13 |
| Country (United States) | 5 of 63 |
| Year (2006) | 5 of 5 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2006-12-04 |
Plantasjen
Kongsvinger, Norway Plantasjen is a garden superstore chain in the Nordic region, providing a wide assortment covering the customers entire need for garden and terrace products as well as decorative flowers and in-house plants. Plantasjen was established in 1986 and is based in Kongsvinger, Norway. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2006-12-18 |
Incisive Media
London, United Kingdom Incisive Media is a business-to-business (B2B) information provider, serving a wide range of financial, business technology, and professional services markets globally. The company provide analyst-grade insight, business intelligence, and access to specialist networks of business professionals around the globe. Its performance-driven marketing solutions give clients bespoke engagement with these valuable audiences and communities. Incisive Media was formed in 1994 and is based in London. |
Buy | £199M |
| Category | Growth Capital Firm |
|---|---|
| Founded | 2001 |
| Size | Small |
| Type | Sector Focused |
Nexus Life Science Partners is a private equity firm that targets private and public healthcare companies located within the United States and around the world. The Firm's focus is on the growth segments of the healthcare industry. In particular, Nexus looks for product-driven life sciences companies developing breakthrough therapeutics for clinical needs, positively altering disease course and associated costs. The firm seeks for each private investment a potential for liquidity within 24 months after initial investment, as well as a 2-3 times return on invested capital. Nexus Life Science Partners was formed in 2001, and is based in New York, New York.
| DEAL STATS | # |
|---|---|
| Overall | 7 of 22 |
| Sector (Life Science) | 6 of 18 |
| Type (IPO) | 3 of 6 |
| State (California) | 2 of 6 |
| Country (United States) | 6 of 19 |
| Year (2006) | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2006-05-15 |
Cambridge Antibody Technology
Gaithersburg, United Kingdom Cambridge Antibody Technology (CATG) is a leader in the development of human monoclonal antibodies as new treatments for disease, having developed a pipeline of novel human monoclonal antibodies. HUMIRA, an antibody for the treatment of rheumatoid arthritis, developed in collaboration with Abbott, is on the market. |
Sell | $702M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2007-02-08 |
Cougar Biotechnology
Raritan, New Jersey, United States Cougar Biotechnology (CGRB) is a biotechnology company established to in-license and develop oncology drugs. Cougar's oncology portfolio includes CB7630, a targeted enzyme inhibitor, which is currently being tested in Phase II clinical trials in prostate cancer; other products are being tested for hematological and solid tumors. |
Sell | - |
